Tiny doses, big impact: Optimizing sedation weaning to reduce opioid use in a Level IV NICU
Open Access
- 29 April 2026
- journal article
- Published by Springer Nature in Journal of Perinatology
Abstract
Objective: Infants in the NICU often require prolonged sedation, increasing risk for iatrogenic withdrawal. We aimed to reduce mean opioid exposure by 20% (26 to 21 days) by May 2023, with sustained improvement through May 2024. Study design: A multidisciplinary team used the Model for Improvement with iterative Plan-Do-Study-Act cycles and EHR tools to implement a standardized sedation-weaning guideline. Applicable outcome, process, and balancing measures were analyzed using statistical process control charts. Results: Among patients receiving >4 days of opioids, mean exposure decreased from 26 to 17 days, length of stay from 70 to 50 days; and overall dexmedetomidine exposure from 18 to 12 days. Adherence to individualized weaning plans improved and feedback indicated effective withdrawal management. Conclusions: Standardized weaning reduced opioid exposure, LOS, and sedative use, enhancing safety, care quality, and NICU capacity.Keywords
This publication has 26 references indexed in Scilit:
- Improved Outcomes With Standardized Convalescent Preterm Respiratory Care PracticesRespiratory Care, 2019
- Implementation of a Risk-Stratified Opioid and Benzodiazepine Weaning Protocol in a Pediatric Cardiac ICUPediatric Critical Care Medicine, 2018
- Implementation of a risk-stratified opioid weaning protocol in a pediatric intensive care unitJournal of Critical Care, 2018
- Prolonged Dexmedetomidine Infusion and Drug Withdrawal In Critically Ill ChildrenThe Journal of Pediatric Pharmacology and Therapeutics, 2017
- Dexmedetomidine and ketamine show distinct patterns of cell degeneration and apoptosis in the developing rat neonatal brainThe Journal of Maternal-Fetal & Neonatal Medicine, 2016
- Effects of Clonidine on Withdrawal From Long-term Dexmedetomidine in the Pediatric PatientThe Journal of Pediatric Pharmacology and Therapeutics, 2015
- The Neurodevelopmental Impact of Neonatal Morphine AdministrationBrain Sciences, 2014
- Use of Benzodiazepines as Anxiolytics in NeonatesAdvances in Neonatal Care, 2014
- The Withdrawal Assessment Tool–1 (WAT–1): An assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients*Pediatric Critical Care Medicine, 2008
- Neonatal abstinence syndrome: assessment and management.1975